X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ClinConnect in partnership with Conduit, will seek to identify, characterize, and validate suitable cocrystal partners for AZD1656 to solve for current challenges associated with solubility, stability, and bioavailability.
Lead Product(s): AZD1656
Therapeutic Area: Immunology Product Name: AZD1656
Highest Development Status: Phase IIProduct Type: Undisclosed
Recipient: ClinConnect
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 11, 2023
Details:
The combined company will accelerate development of Conduit’s autoimmune disease and idiopathic male infertility pipeline, including AZD5904, a potent orally bioavailable MPO inhibitor.
Lead Product(s): AZD5904
Therapeutic Area: Endocrinology Product Name: AZD5904
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Murphy Canyon Acquisition
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger September 22, 2023
Details:
AZD5904 is a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
Lead Product(s): AZD5904
Therapeutic Area: Endocrinology Product Name: AZD5904
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Murphy Canyon Acquisition Corp.
Deal Size: $27.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 09, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
